VEGFA and prostate carcinoma: In addition, the tyrosine kinase inhibitor pazopanib, which targets VEGF and PDGF receptors [62], is currently undergoing clinical investigation in prostate cancer in the castrate-resistant setting (NCT00454571, NCT00486642, NCT00945477).